{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:48:38Z","timestamp":1772765318605,"version":"3.50.1"},"reference-count":29,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,11,16]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>FOLFOX regimen is a chemotherapy regimen commonly used to treat colorectal cancers and other gastrointestinal malignancies. It comprises a combination of drugs, including leucovorin, 5-fluorouracil and oxaliplatin. Hypokalaemia can be a potential adverse drug reaction to the FOLFOX regimen, along with other haematological or metabolic adverse effects. Causes for hypokalaemia include chemotherapy-induced diarrhoea, nausea, vomiting and increased renal loss of potassium. The oxaliplatin used in the FOLFOX regimen is often associated with hypokalaemia due to intracellular shift, secondary to using 5% dextrose for infusion. Therefore, close monitoring of electrolyte levels, including potassium, is essential during chemotherapy treatment. Patients may require supplementation with potassium, either orally or intravenously, to maintain adequate levels and prevent complications. Additionally, managing diarrhoea, nausea and vomiting can help minimise potassium loss during chemotherapy. This case describes a patient who developed severe hypokalaemia (1.4\u2009mmol\/L) associated with the use of the FOLFOX regimen without any cardiac arrhythmia.<\/jats:p>","DOI":"10.1136\/bcr-2024-261012","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T03:55:48Z","timestamp":1734753348000},"page":"e261012","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["FOLFOX regimen induced severe hypokalaemia with hypocalcaemia and hypomagnesaemia"],"prefix":"10.1136","volume":"17","author":[{"given":"Manjappa","family":"Mahadevappa","sequence":"first","affiliation":[{"name":"Department of Cardiology, JSS Medical college and Hospital, Mysore, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran Pura","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, JSS Medical college and Hospital, Mysore, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakeer","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, JSS College of Pharmacy, Mysore, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh S","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Surgical Gastroenterology, JSS Medical college and Hospital, Mysore, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2025082800004325000_17.12.e261012.1","first-page":"41","article-title":"Drugs of choice for cancer","volume":"1","year":"2003","journal-title":"Treat Guidel Med Lett"},{"key":"2025082800004325000_17.12.e261012.2","unstructured":"Hegde VS , Leucovorin NS . Leucovorin. In: xPharm: The Comprehensive Pharmacology Reference. 2023: 1\u20134. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553114\/"},{"key":"2025082800004325000_17.12.e261012.3","unstructured":"McEvoy GK . Google books. In: AHFS Drug Information 2004. American Society of Health-System Pharmacists, 2004. Available: https:\/\/books.google.co.in\/books\/about\/AHFS_Drug_Information_2004.html?id=l-5IPgAACAAJ&redir_esc=y"},{"key":"2025082800004325000_17.12.e261012.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002083220602"},{"key":"2025082800004325000_17.12.e261012.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040958"},{"key":"2025082800004325000_17.12.e261012.6","first-page":"e733","article-title":"Impact of the Localization of the Primary Tumor and RAS\/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial","volume":"17","author":"Noepel-Duennebacke","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"2025082800004325000_17.12.e261012.7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1179\/1973947815Y.0000000048","article-title":"Hypersensitivity reaction caused by folinic acid administration: a case report and literature review","volume":"28","author":"Florit-Sureda","year":"2016","journal-title":"J Chemother"},{"key":"2025082800004325000_17.12.e261012.8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaci.2014.09.045","article-title":"Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations","volume":"135","author":"Ure\u00f1a-Tavera","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2025082800004325000_17.12.e261012.9","unstructured":"Hegde VS , Nagalli S . Leucovorin. StatPearls Publishing, 2020. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553114\/"},{"key":"2025082800004325000_17.12.e261012.10","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.9.33"},{"key":"2025082800004325000_17.12.e261012.11","doi-asserted-by":"publisher","DOI":"10.3747\/co.v18i1.708"},{"key":"2025082800004325000_17.12.e261012.12","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214558350"},{"key":"2025082800004325000_17.12.e261012.13","first-page":"249","article-title":"Management of oxaliplatin-induced peripheral neuropathy","volume":"1","author":"Saif","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"2025082800004325000_17.12.e261012.14","unstructured":"Devanabanda B , Kasi A . Oxaliplatin. StatPearls Publishing, 2021. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557690\/"},{"key":"2025082800004325000_17.12.e261012.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390707"},{"key":"2025082800004325000_17.12.e261012.16","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(67)90233-5"},{"key":"2025082800004325000_17.12.e261012.17","doi-asserted-by":"publisher","DOI":"10.1152\/advan.00121.2016"},{"key":"2025082800004325000_17.12.e261012.18","first-page":"138","article-title":"Severe hypomagnesemia with secondary hypocalcaemia (HSH) presenting as recurrent self terminating Torsades de pointes","volume":"4","author":"Mahadevappa","year":"2020","journal-title":"IHJ Cardiovasc Case Rep (CVCR)"},{"key":"2025082800004325000_17.12.e261012.19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","article-title":"Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management","volume":"80","author":"Oronsky","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025082800004325000_17.12.e261012.20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00779","article-title":"Electrolyte Disorders Induced by Antineoplastic Drugs","volume":"10","author":"Verzicco","year":"2020","journal-title":"Front Oncol"},{"key":"2025082800004325000_17.12.e261012.21","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-200207000-00006"},{"key":"2025082800004325000_17.12.e261012.22","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025082800004325000_17.12.e261012.23","first-page":"2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"2025082800004325000_17.12.e261012.24","first-page":"10118597","article-title":"Focusing on the preventability of adverse drug reactions","volume":"27","author":"Schumock","year":"1992","journal-title":"Hosp Pharm"},{"key":"2025082800004325000_17.12.e261012.25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm080"},{"key":"2025082800004325000_17.12.e261012.26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00228-008-0474-x","article-title":"A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance","volume":"64","author":"Basso","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"2025082800004325000_17.12.e261012.27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/02841860903464015","article-title":"An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women","volume":"49","author":"Chay","year":"2010","journal-title":"Acta Oncol"},{"key":"2025082800004325000_17.12.e261012.28","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-010-0050-0"},{"key":"2025082800004325000_17.12.e261012.29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40487-019-00102-3","article-title":"Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia","volume":"8","author":"Giampieri","year":"2020","journal-title":"Oncol Ther"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-261012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:00:58Z","timestamp":1756364458000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-261012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,20]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bcr-2024-261012"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-261012","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}